Want to join the conversation?
$CELG 2Q15 Call: ABRAXANE posted strong 9% sequential growth & 13% year-over-year growth driven primarily by ongoing launch of pancreatic cancer across Europe. We also launched ABRAXANE in non-small-cell lung cancer in Europe. We expect solid future growth in Europe for ABRAXANE.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.